Targeting Dysbiosis for the Treatment of Liver Disease

Abstract The gut microbiome is composed of a vast number of microbes in the gastrointestinal tract, which benefit host metabolism, aid in digestion, and contribute to normal immune function. Alterations in microbial composition can result in intestinal dysbiosis, which has been implicated in several diseases including obesity, inflammatory bowel disease, and liver diseases. Over the past several years, significant interactions between the intestinal microbiota and liver have been discovered, with possible mechanisms for the development as well as progression of liver disease and promising therapeutic targets to either prevent or halt the progression of liver disease. In this review the authors examine mechanisms of dysbiosis-induced liver disease; highlight current knowledge regarding the role of dysbiosis in nonalcoholic liver disease, alcoholic liver disease, and cirrhosis; and discuss potential therapeutic targets.

[1]  Brian Goodman,et al.  The microbiome and cancer , 2018, The Journal of pathology.

[2]  Kyle Bittinger,et al.  Engineering the gut microbiota to treat hyperammonemia. , 2015, The Journal of clinical investigation.

[3]  H. Dupont,et al.  New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  B. Neuschwander‐Tetri,et al.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD , 2015, Diabetes Care.

[5]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  J. Turner,et al.  Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice , 2015, Hepatology.

[7]  Jing Li,et al.  Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease , 2015, Scientific Reports.

[8]  Remo Frei,et al.  Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence , 2015, Current opinion in gastroenterology.

[9]  S. Yooseph,et al.  Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. , 2014, Cell metabolism.

[10]  Y. Chawla,et al.  Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. , 2014, Gastroenterology.

[11]  Zheng Zhang,et al.  The global burden of liver disease: The major impact of China , 2014, Hepatology.

[12]  N. Arslan,et al.  Obesity, fatty liver disease and intestinal microbiota. , 2014, World journal of gastroenterology.

[13]  L. Eusebi,et al.  Gut microbiota and metabolic syndrome. , 2014, World journal of gastroenterology.

[14]  R. Francés,et al.  Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[16]  Kouichi Miura,et al.  TOPIC HIGHLIGHT , 2014 .

[17]  Daniel M. Saman,et al.  Recovery of the Gut Microbiome following Fecal Microbiota Transplantation , 2014, mBio.

[18]  B. Sharma,et al.  Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  A. Alisi,et al.  Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  T. Kanai,et al.  Role of Toll-Like Receptors in Immune Activation and Tolerance in the Liver , 2014, Front. Immunol..

[21]  C. Hill,et al.  Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut , 2014, Proceedings of the National Academy of Sciences.

[22]  Andmorgan R. Fisher,et al.  Altered profile of human gut microbiome is associated with cirrhosis and its complications. , 2014, Journal of hepatology.

[23]  R. Stravitz,et al.  Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis , 2014, Alimentary pharmacology & therapeutics.

[24]  S. Macfarlane.  Antibiotic treatments and microbes in the gut. , 2014, Environmental microbiology.

[25]  K. Kowdley,et al.  Controversies in the Diagnosis and Management of NAFLD and NASH. , 2014, Gastroenterology & hepatology.

[26]  R. Malekzadeh,et al.  Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. , 2014, The American journal of clinical nutrition.

[27]  Lawrence A. David,et al.  Diet rapidly and reproducibly alters the human gut microbiome , 2013, Nature.

[28]  A. Moya,et al.  Differential Effects of Antibiotic Therapy on the Structure and Function of Human Gut Microbiota , 2013, PloS one.

[29]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[30]  Lihua Chen,et al.  Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. , 2013, World journal of gastroenterology.

[31]  Jorge Henao-Mejia,et al.  Role of the intestinal microbiome in liver disease. , 2013, Journal of autoimmunity.

[32]  James B. Mitchell,et al.  Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity , 2013, Nature Communications.

[33]  Masoumeh Sikaroodi,et al.  Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  V. Wong,et al.  NAFLD in Asia—as common and important as in the West , 2013, Nature Reviews Gastroenterology &Hepatology.

[35]  Fei Li,et al.  FXR signaling in the enterohepatic system , 2013, Molecular and Cellular Endocrinology.

[36]  Andmorgan R. Fisher,et al.  Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy , 2013, PloS one.

[37]  V. Wong,et al.  Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. , 2013, Annals of hepatology.

[38]  E. Comelli,et al.  Intestinal microbiota in patients with nonalcoholic fatty liver disease , 2013, Hepatology.

[39]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[40]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[41]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[42]  J. Petrosino,et al.  Metagenomic Analyses of Alcohol Induced Pathogenic Alterations in the Intestinal Microbiome and the Effect of Lactobacillus rhamnosus GG Treatment , 2013, PloS one.

[43]  Rubén Francés,et al.  Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[44]  V. Shah,et al.  The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension , 2012, Clinical and molecular hepatology.

[45]  S. Rabot,et al.  Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice , 2012, Gut.

[46]  R. Loomba,et al.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease , 2012, Alimentary pharmacology & therapeutics.

[47]  J. Gordon,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[48]  V. Tremaroli,et al.  Functional interactions between the gut microbiota and host metabolism , 2012, Nature.

[49]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[50]  H. Rangwala,et al.  Colonic microbiome is altered in alcoholism. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[51]  F. Galvano,et al.  Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis , 2012, Digestive Diseases and Sciences.

[52]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[53]  Claudia Cesaro,et al.  Rifaximin in the treatment of hepatic encephalopathy , 2011, Hepatic medicine : evidence and research.

[54]  A. Gastaldelli,et al.  Diabetes and Nonalcoholic Fatty Liver Disease , 2011, Experimental diabetes research.

[55]  A. Webster,et al.  Probiotics for patients with hepatic encephalopathy. , 2011, The Cochrane database of systematic reviews.

[56]  D. D. de Luis,et al.  Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. , 2011, European review for medical and pharmacological sciences.

[57]  Baoli Zhu,et al.  Characterization of fecal microbial communities in patients with liver cirrhosis , 2011, Hepatology.

[58]  J. Auwerx,et al.  The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.

[59]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[60]  J. Bosch,et al.  Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis , 2010, Hepatology.

[61]  Y. Chawla,et al.  Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. , 2010, Journal of hepatology.

[62]  E. Want,et al.  Systemic gut microbial modulation of bile acid metabolism in host tissue compartments , 2010, Proceedings of the National Academy of Sciences.

[63]  M. Barone,et al.  Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[64]  J. Söderholm,et al.  Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate† , 2010, Inflammatory bowel diseases.

[65]  F. Galvano,et al.  Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy , 2010, European journal of gastroenterology & hepatology.

[66]  A. Keshavarzian,et al.  Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. , 2009, Alcoholism, clinical and experimental research.

[67]  B. Runyon.  Management of adult patients with ascites due to cirrhosis: An update , 2009 .

[68]  R. Rao.  Endotoxemia and gut barrier dysfunction in alcoholic liver disease , 2009, Hepatology.

[69]  S. Sarin,et al.  Small‐intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease , 2009, Alimentary pharmacology & therapeutics.

[70]  G. La Torre,et al.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease , 2009, Hepatology.

[71]  A. Keshavarzian,et al.  Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. , 2009, Alcohol.

[72]  C. McClain,et al.  Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. , 2008, Alcohol.

[73]  A. Horská,et al.  The effect of a probiotic on hepatic steatosis. , 2008, Journal of clinical gastroenterology.

[74]  Gregory Gores1,et al.  Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease , 2008, Seminars in liver disease.

[75]  A. Dolganiuc,et al.  The critical role of toll‐like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88 , 2008, Hepatology.

[76]  I. Novotný,et al.  The effect of probiotics on gut flora, level of endotoxin and Child–Pugh score in cirrhotic patients: results of a double-blind randomized study , 2007, European journal of gastroenterology & hepatology.

[77]  P. Adegboyega,et al.  Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. , 2007, Journal of hepatology.

[78]  T. Gheyi,et al.  Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. , 2007, The Biochemical journal.

[79]  B. Lacy,et al.  Small intestinal bacterial overgrowth: a comprehensive review. , 2007, Gastroenterology & hepatology.

[80]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[81]  M. McCarthy,et al.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice , 2006, Proceedings of the National Academy of Sciences.

[82]  A. Dolganiuc,et al.  Pattern recognition receptors: A contemporary view on liver diseases , 2006, Hepatology.

[83]  C. De Simone,et al.  Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases , 2005, Journal of clinical gastroenterology.

[84]  Ting Wang,et al.  The gut microbiota as an environmental factor that regulates fat storage. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[85]  P. Sheth,et al.  L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[86]  G. Gores,et al.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .

[87]  G. Gores,et al.  O0040 FREE FATTY ACIDS PROMOTE HEPATIC LIPOTOXICITY BY STIMULATING TNF‐ALPHA EXPRESSION VIA A LYSOSOMAL PATHWAY , 2004, Journal of Pediatric Gastroenterology and Nutrition.

[88]  M. Thangavel,et al.  Epidermal growth factor prevents acetaldehyde-induced paracellular permeability in Caco-2 cell monolayer. , 2004, Alcoholism, clinical and experimental research.

[89]  S. Riordan,et al.  Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis , 2004, Hepatology.

[90]  D. Polk,et al.  Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells* , 2002, The Journal of Biological Chemistry.

[91]  J. Aponte,et al.  Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia , 2002, American Journal of Gastroenterology.

[92]  A. Federico,et al.  Gut-liver axis: a new point of attack to treat chronic liver damage? , 2002, American Journal of Gastroenterology.

[93]  F. Rodríguez-Valera,et al.  Detection and identification of bacterial DNA in patients with cirrhosis and culture‐negative, nonneutrocytic ascites , 2002, Hepatology.

[94]  G. Macfarlane,et al.  Gastrointestinal effects of prebiotics , 2002, British Journal of Nutrition.

[95]  J. Aponte,et al.  Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis , 2001, American Journal of Gastroenterology.

[96]  S. Vogel,et al.  Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. , 2001, Alcoholism, clinical and experimental research.

[97]  T. Risby,et al.  Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. , 2000, Gastroenterology.

[98]  C. Bode,et al.  Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. , 2000, Journal of hepatology.

[99]  K. Kailasapathy,et al.  Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. , 2000, Immunology and cell biology.

[100]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[101]  M. Montalto,et al.  Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects. , 1997, Hepato-gastroenterology.

[102]  C. Guarner,et al.  Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. , 1997, Journal of hepatology.

[103]  B. Flourié,et al.  Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. , 1997, The Journal of nutrition.

[104]  A. Nanji,et al.  Lactobacillus Feeding Reduces Endotoxemia and Severity of Experimental Alcoholic Liver (Disease) , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[105]  M. Merli,et al.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. , 1990, Journal of clinical gastroenterology.

[106]  A. Read,et al.  Lactobacillus acidophilus (Enpac) in Treatment of Hepatic Encephalopathy , 1966, British medical journal.

[107]  Fenton Jc,et al.  TREATMENT OF HEPATIC ENCEPHALOPATHY BY ALTERATION OF INTESTINAL FLORA WITH LACTOBACILLUS ACIDOPHILUS. , 1965 .

[108]  K. Nelson,et al.  Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. , 2015, Gastroenterology.

[109]  R. Rao.  Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. , 2008, Methods in molecular biology.

[110]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[111]  L. Grande,et al.  Bacterial translocation of enteric organisms in patients with cirrhosis. , 2001, Journal of hepatology.